The Healing Capability of Clove Flower Extract (CFE) in Streptozotocin-Induced (STZ-Induced) Diabetic Rat Wounds Infected with Multidrug Resistant Bacteria

Rewaa Ali 1,*, Tarek Khamis 2, Gamal Enan 3,∗, Gamal El-Didamony 3, Basel Sitohy 4,5,∗ and Gamal Abdel-Fattah 1,6

1 Department of Botany, Faculty of Science, Mansoura University, Mansoura 35516, Egypt; abdefattaham@yahoo.com
2 Department of Pharmacology, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44519, Egypt; gamal.enan@zu.edu.eg
3 Department of Botany and Microbiology, Faculty of Sciences, Zagazig University, Zagazig 44511, Egypt; eldidamonyg@gmail.com
4 Department of Radiation Sciences, Oncology, Umeå University, SE-90185 Umea, Sweden; basel.sitohy@umu.se
5 Department of Clinical Microbiology Infection and Immunology, SE-90185 Umea, Sweden
6 Correspondence: rewaaafifi85@gmail.com (R.A.); gamalenan@ymail.com (G.E.)

Abstract: Treatment of diabetic foot ulcer (DFU) is of great challenge as it is shown to be infected by multidrug resistant bacteria (MDR bacteria). Sixty four bacterial isolates were isolated from DFU cases; antibiotic susceptibility tests were carried out for all of them. One bacterial isolate (number 11) was shown to resist the action of 8 out of 12 antibiotics used and was identified by both a Vitek-2 system and 16S rRNA fingerprints as belonging to Proteus mirabilis, and was designated Proteus mirabilis LC587231 (P. mirabilis). Clove flower extract (CFE) inhibited distinctively the P. mirabilis bacterium obtained. GC-MS spectroscopy showed that this CFE contained nine bioactive compounds. The effect of CFE on wound healing of Type 1 diabetic albino rats (Rattus norvegicus) was studied. The results indicated that topical application of CFE hydrogel improved wound size, wound index, mRNA expression of the wound healing markers (Col1, MMP9, Fibronectin, PCNA, and TGFβ), growth factor signaling pathways (PPAR-α, PGC1-α, GLP-1, GLP-1r, EGF-β, EGF-βr, VEGF-β, and FGF-β), inflammatory cytokine expression (IL8, TNFa, NFKβ, IL1β, and MCP1), as well as anti-inflammatory cytokines (IL4 & IL10), pro-apoptotic markers (FAS, FAS-L, BAX, BAX/BCL-2, Caspase-3, P53, P38), as well as an antiapoptotic one (BCL2). Furthermore, it improved the wound oxidative state and reduced the wound microbial load, as the cefepime therapy improved the wound healing parameters. Based on the previous notions, it could be concluded that CFE represents a valid antibiotics alternative for DFU therapy since it improves diabetic wound healing and exerts antibacterial activity either in vitro or in vivo.

Keywords: diabetic foot ulcer; MDR- Proteus mirabilis; inflammatory markers; Syzygium aromaticum; growth factor

1. Introduction

Diabetic foot ulcers and their infections are common complications associated with diabetic foot diseases; these complications are common cause of morbidity and impose a substantial burden on the patient and society [1]. The diabetic foot infection is eventually associated with an inflammatory response and tissue injury that could aggravate the clinical spectrum from simple, superficial cellulitis to chronic osteomyelitis [2]. A significant problem facing physicians in the treatment of diabetic foot ulcer (DFU) is the existence of multidrug-resistant (MDR) microbes, where many variants of MDR microbes have been isolated and characterized [3–11]. MDR- P. mirabilis is one of the most prevalent microbes to
exist in diabetic foot ulcers (DFU) [12]. There is a vast need to search for other innovative therapies based on using natural plant extract either singly or in combination with antibiotics [11], probiotics [3,13–17], natural and modified proteins [18,19], nanoparticles [20], and phage therapy [21].

Peripheral diabetic complications, such as neuropathy, angiopathy, and the infections of the DFU extend the inflammatory stage with the overexpression of inflammatory cytokines such as $\text{IL-1}\beta$ [22], $\text{IL-6}$ [23], $\text{TNF-}\alpha$ [23], $\text{NF-}\kappa\beta$ [24], and $\text{MCP-1}$ [25], which increase the tissue damage, imposing either a proliferative or maturation stage, which results in retarding the diabetic wound healing [26]. Several medicinal herbal extracts have achieved reasonable therapeutic goals regarding DFU infection [27]. $\text{S. aromaticum}$ is one of those herbs, belong to the family Myrtaceae, and exerts broad-spectrum antibacterial activity against MDR bacteria [28] and has other beneficial biological activities such as anti-inflammatory, antioxidant, and antibacterial effects [29]. The anti-inflammatory effect was recognized as one of the most beneficial effects regarding the medicinal plant that reduces the unnecessary inflammatory response, thus, preventing further tissue damage and increased expression of T helper lymphocytes (Th2), which regulate the inflammatory process and minimize the unnecessary inflammatory cascade [30]. $\text{S. aromaticum}$ is traditionally used in the treatment of wounds, burns, and tooth affection as a pain reliever, as well as treating tooth infection and toothache. Additionally, it is used in several industrial processes such as soap, perfumes, and in cleaning vehicles [31]. Interestingly, CFE used in Indian and Chinese traditional medicine [32]. CFE contains several bioactive compounds which are known for their anti-inflammatory effects, via switching of TNF-\alpha inflammatory cascades and inducing $\text{Nrf-2}$, which is considered the major anti-inflammatory pathway [33]. Also, they exert a broad antibacterial spectrum against several pathogens [34]. Several studies published recently used topical hydrogel-based plant extracts in treatment of either skin infections or as having wound healing potential. For instance, Antonescue et al. [35,36] studied the pharmacological effects of $\text{Ocimum basilicum}$ and $\text{Trifolium pratense}$ either singly or in combination of both of them; they showed to be superior in their wound healing potential.

The present study was designed to investigate the phytochemical profile of the CFE and its therapeutic potential in the treatment of a multidrug-resistant $\text{P. mirabilis}$ LC587231-infected diabetic excisional wound model as an antibiotic alternative for DFU therapy, as well as to study the underlying mechanisms for the healing process.

2. Results

2.1. Characterization of the Bacterial Isolates Obtained and Their Antibiotic Bioassay

Gram staining was carried out for the 64 bacterial isolates obtained. About 33 bacterial isolates and 31 bacterial isolates were $\text{G}^+$ and $\text{G}^-$ bacteria, respectively (Supplementary Table S1). The antibiotic sensitivity test was carried out for those 64 bacterial isolates. Results are given in Supplementary Table S1. Except for the bacterial isolates DFU 9, 11, 16, and 32, all isolates showed variability in their sensitivity or resistance to the 13 antibiotics investigated; such bacterial isolates DFU 9, 11, 16, and 32 were showed to be multidrug resistant as they possessed higher MAR indices of about 30.7, 53.8, 23.1, and 23.1%, respectively (Supplmentary Table S1). The MDR isolates DFU 9, 11, 16, and 32 were identified by a Vietek-2 system and were shown to be strains belonging to $\text{Morganella morgani}$, $\text{Proteus mirabilis}$, $\text{Serrataia fonticola}$, and $\text{Escherichia coli}$, respectively (Table 1). $\text{P. mirabilis}$ DFU11 was of interest as it was dominant within the bacterial isolates obtained and possessed the highest MAR index. Consequently, it was identified at the molecular level by the sequencing of 16S rRNA which confirmed the biochemical identification carried out by the Vietek-2 system. The bacterium $\text{P. mirabilis}$ was deposited in the NCBI with accession number LC587231 (Supplementary Figure S1). Since $\text{P. mirabilis}$ LC587231 resisted the action of ampicillin, ampicillin/sulbacreram, aztreonam, cefazolin, cefepime, ceftriaxone, tigecycline, and nitrofuran, it was used for further work in this study.
Table 1. Selection and Identification of antibiotic-resistant isolates.

| No | Biochemical Tests                  | Abbreviations | Morganella monganii | Proteus mirabilis | Serratia fonticola | Escherichia coli |
|----|-----------------------------------|---------------|---------------------|-------------------|-------------------|-----------------|
| 1  | Ala-phe-pro-arylamidase            | APPA          | −                    | −                  | −                  | −               |
| 2  | Hydrogen sulfide production       | H2S           | +ve                 | +ve               | +ve               | −               |
| 3  | Beta-glucosidase                  | BGLu          | −                    | −                  | +ve               | −               |
| 4  | L-proline arylamidase             | ProA          | −                    | −                  | −                  | +ve             |
| 5  | Saccharose/Sucralose              | SAC           | −                    | −                  | −                  | +ve             |
| 6  | L-Lactate alkanilization          | LLATK         | +ve                 | +ve               | +ve               | +ve             |
| 7  | Glycine arylamidase               | GlyA          | −                    | −                  | −                  | −               |
| 8  | O/129 Resistance                  | O129R         | +ve                 | +ve               | +ve               | +ve             |
| 9  | Adonitol                          | ADO           | −                    | −                  | −                  | +ve             |
| 10 | Beta-N-Acetyl-glucose aminidase    | BNAG          | −                    | −                  | −                  | −               |
| 11 | D-Maltose                         | dMAL          | −                    | −                  | +ve               | +ve             |
| 12 | Lipase                            | LiP           | −                    | −                  | −                  | −               |
| 13 | d-Tagatose                        | dTAG          | −                    | −                  | −                  | −               |
| 14 | Alpha-glucosidase                 | AGLu          | −                    | −                  | +ve               | −               |
| 15 | Ornithine decarboxylase           | ODC           | +ve                 | +ve               | −                  | −               |
| 16 | Glu-Gly-Arg-Arylamidase           | GGA            | +ve                 | +ve               | −                  | −               |
| 17 | L-pyrrolidonyl-arylaminidase      | PyrA          | −                    | −                  | −                  | −               |
| 18 | Glutamyl arylamidase PNA          | AGLTP         | +ve                 | +ve               | −                  | −               |
| 19 | D-Mannitol                        | dMAN          | −                    | −                  | +ve               | +ve             |
| 20 | Palatinose                        | PLE           | −                    | −                  | +ve               | +ve             |
| 21 | D-Trehalose                       | dTRE          | −                    | −                  | +ve               | −               |
| 22 | Succinate alkanilization          | SuCT          | +ve                 | +ve               | +ve               | +ve             |
| 23 | Lysine decarboxylase              | LDC           | −                    | −                  | −                  | +ve             |
| 24 | I-Malate assimilation             | IMLTa         | +ve                 | +ve               | +ve               | +ve             |
| 25 | L-Arabitol                        | HARL          | −                    | −                  | −                  | +ve             |
| 26 | D-Glucose                         | dGLu          | +ve                 | +ve               | +ve               | +ve             |
| 27 | D-Mannose                         | dMNE          | +ve                 | +ve               | +ve               | +ve             |
| 28 | Tyrosine arylamidase              | TyrA          | +ve                 | +ve               | +ve               | +ve             |
| 29 | Citrate (Sodium)                  | CIT           | −                    | +ve               | +ve               | +ve             |
| 30 | Beta-N-Acetyl-galactosaminidase    | NAGA          | −                    | −                  | −                  | −               |
| 31 | D-Mannitol                        | SHISa         | −                    | −                  | −                  | −               |
| 32 | ELLMAN                            | ELLM          | +ve                 | +ve               | +ve               | −               |
| 33 | D-Cellobiose                      | dCEL          | −                    | −                  | −                  | −               |
| 34 | Gamma-Glutamyl transferase        | GGT           | +ve                 | +ve               | +ve               | +ve             |
| 35 | Beta-Xylosidase                   | lxy1          | −                    | −                  | −                  | −               |
| 36 | Urease                            | URE           | +ve                 | +ve               | +ve               | +ve             |
| 37 | Malonate                          | MNT           | −                    | −                  | −                  | −               |
| 38 | Alpha-galactosidase               | AGAL          | −                    | −                  | −                  | +ve             |
| 39 | Coumarate                         | CMT           | +ve                 | +ve               | +ve               | +ve             |
| 40 | L-lactate assimilation            | ILATa         | −                    | −                  | −                  | +ve             |
| 41 | Beta-galactosidase                | BGAL          | −                    | −                  | −                  | +ve             |
| 42 | Fermentation glycose              | OFF           | +ve                 | +ve               | +ve               | +ve             |
| 43 | Beta-alanine arylamidase PNA      | BALaP         | −                    | −                  | −                  | −               |
| 44 | D-Sorbitol                        | dSOR          | −                    | −                  | −                  | +ve             |
| 45 | 5-Keto-D-gluconate                | SKG           | −                    | −                  | −                  | −               |
| 46 | Phosphatase                       | PHOS          | +ve                 | +ve               | +ve               | +ve             |
| 47 | Beta-Gluconoridase                | BGUR          | −                    | −                  | −                  | −               |

The antibiotic cefepime is one of choice in treatment of diabetic food infections in Egypt and it is available in Egyptian market. Consequently, the inhibition of *P. mirabilis* isolated from diabetic foot biopsy by higher concentrations of cefepime was a necessary
goal. Thus, the MIC of the antibiotic cefepime was determined against the *P. mirabilis* bacterium isolated from diabetic foot biopsy. The *P. mirabilis* was resistant to 10–49 µg/mL cefepime. MIC was shown to be 50 µg/mL and MBC was 60 µg/mL (Table 2). Therefore, higher concentrations of the antibiotic cefepime were used in further experiments. About 20 mg/mL (1 g/50 mL) was used, as it is available and prepared in Egyptian pharmacies.

Table 2. Minimum inhibitory concentrations (MICs) of the antibiotic cefepime and clove flower extract (CFE).

| Concentration of the Antimicrobial Agents | Growth of *P. mirabilis* |
|----------------------------------------|-------------------------|
| Cefepime (µg/mL)                       |                         |
| 10                                     | Positive                |
| 20                                     | Positive                |
| 30                                     | Positive                |
| 40                                     | Positive                |
| 50                                     | No growth               |
| CFE (µg/mL)                            |                         |
| 2                                      | Positive                |
| 4                                      | Positive                |
| 6                                      | Positive                |
| 8                                      | Negative                |
| 10                                     | Negative                |

2.2. Phytochemical Screening of CFE and In Vitro Antibacterial Activity

The GC-Mass running times for CFE were 57 min. The GC-Mass phytochemical screening of CFE was done with the aid of the National Institute Standard and Technology (NIST). The spectrum of the screened unknown compounds were compared with the NIST stored known spectra and revealed nine bioactive compounds (Table 3 and Figure 1). Supplementary data (Figures S2 and S3) show that eugenol represented the higher abundance among the identified bioactive compounds (Table 3 and Supplementary data (Figures S2 and S3)). Moreover, CFE showed in vitro antibacterial activity against *P. mirabilis*, as inhibition zones of about ≥20 mm were detected in lawns of *P. mirabilis* around wells containing CFE. As given in Table 2, the MIC CFE was 8 µg/mL. Minimum bactericidal concentration (MBC) was 10 µg/mL.

Table 3. GC-Mass analysis report for the clove ethanolic extract.

| RT/min | Name & Class                        | Mol. Formula | Mol. wt | Area  | Base Peak (100%) |
|--------|------------------------------------|--------------|---------|-------|------------------|
| 13.78  | Eugenol (Phenol)                   | C₁₀H₁₂O₂     | 164.0   | 82.34 | 77.00            |
| 14.40  | Caryophyllene (Bicyclic)           | C₁₅H₂₀₄      | 204.0   | 3.20  | 133.0 & 93.00    |
| 16.47  | 3-Allyl-6-methoxyphenyl acetate     | C₁₅H₂₄O₂     | 204.0   | 0.26  | 161.0            |
| 17.04  | Phenol, 2-methoxy-4-(2-propenyl)-, acetate | C₁₂H₁₄O₃ | 206.0   | 0.24  | 164.0            |
| 17.79  | Caryophyllene oxide (Bicyclic)     | C₁₅H₂₄O      | 220.0   | 0.48  | 41.00            |
| 19.06  | Caryophylla-4(12),8(13)-diien-5a-ol | C₁₅H₂₄O      | 220.0   | 0.42  | 136.0            |
| 20.15  | Benzene, 1,4-dimethyl-2-[(3-methylphenyl)methyl] | C₁₆H₁₈ | 210    | 0.12  | 195              |
| 43.05  | Butanoic acid, 3-methyl-            | C₁₅H₂₅O₂     | 248.0   | 0.27  | 164.0            |
| 49.51  | α-sitosterol (steroid)              | C₂₉H₄₆O       | 414.0   | 0.84  | 107.0            |

2.3. Validation of Type 1 Diabetic and Diabetic Wound Onset

The results of the present investigation illustrated that the streptozotocin (STZ), intraperitoneally injected in rats, lead to the development of both sustained elevations in blood glucose level ≥500 mg/dL and a sharp decrease in serum insulin level <3.5 mIU/mL (Figure 2A,B) with a progressive decrease in body weight within the first 3 weeks of diabetic induction. This was correlated with a clear manifestation of polydipsia, polyuria, monitored with water intake and little moisture content, and polyphagia, monitored with daily feed intake of the rats investigated. Moreover, three days post diabetic wound curation and infection with *P. mirabilis*, the wound showed signs of suppuration and local bacterial infection without the development of any signs of systemic bacterial infection (Figure 3).
Table 3. GC-Mass analysis report for the clove ethanolic extract.

| RT/min | Name & Class            | Mol. Formula | Mol. wt | Area Base Peak (100%) |
|-------|-------------------------|--------------|---------|----------------------|
| 13.78 | Eugenol (Phenol)        | C_{10}H_{12}O_{2} | 164.0   | 82.34 77.00          |
| 14.40 | Caryophyllene (Bicyclic)| C_{15}H_{24}  | 204.0   | 3.20 133.0 93.00     |
| 16.47 | 3-Allyl-6-methoxyphenyl acetate | C_{15}H_{24}  | 204.0   | 0.26 161.0          |
| 17.04 | Phenol, 2-methoxy-4-(2-propenyl)-, acetate | C_{12}H_{14}O_{3} | 206.0 | 0.24 164.0          |
| 17.79 | Caryophyllene oxide (Bicyclic) | C_{15}H_{24}O | 220.0   | 0.48 41.00          |
| 19.06 | Caryophylla-4(12),8(13)-dien-5à-ol | C_{15}H_{24}O | 220.0 | 0.42 136.0          |
| 20.15 | Benzene, 1,4-dimethyl-2-[(3-methylphenyl)methyl] | C_{16}H_{18}  | 210.0   | 0.12 195            |
| 43.05 | Butanoic acid, 3-methyl-, 2-methoxy-4-(2-propenyl)phenyl ester | C_{15}H_{20}O_{3} | 248.0 | 0.27 164.0          |
| 49.51 | α-sitosterol (steroid) | C_{29}H_{50}O | 414.0   | 0.84 107.0         |

Figure 1. Chemical structure of the GC-MASS-screened Syzygium aromaticum ethanolic extract bioactive compounds (A–J).

Figure 2. Glycemic (A,B) and wound parameters of Type 1 diabetic rats throughout 21 days. Fasting blood glucose level (mg/dL) (A), serum insulin level (mIU/l) (B), wound diameter (cm) (C) and wound index (D).
Figure 3. Wound imaging follow-up on the 1st, 3rd, 6th, 9th, 12th, 15th, and 18th days. (three days post diabetic wound curation and infection with *P. mirabilis*).
2.4. Effect of CFE and Cefepime on Wound Healing

It was illustrated that both CFE and cefepime topical application caused a significant ($p < 0.001$) reductions in the mean value of wound size and wound index when compared with diabetic rats with the rank of CFE, followed by the cefepime-treated group (Figures 2C,D and 3).

2.5. Effect of CFE and Cefepime on the Expression of Wound Healing Markers and Collagen Deposition

The results obtained herein indicated that the topical application of CFE significantly upregulated the mean fold change of the mRNA expression of the healing biomarkers: PCNA, Colagen-1, MMP-9, Fibronectin, and collagen either compared with the diabetic group ($p < 0.001$) or cefepime-treated group ($p < 0.01$). However, the cefepime-treated group showed a significant upregulation in the mean fold change of the mRNA expression of fibronectin, MMP-9 ($p < 0.001$), and colI ($p < 0.05$) when compared with the diabetic group (Figure 4A–F).

![Figure 4](image-url)

**Figure 4.** Effect of the hydrogel topical application of cefepime and CFE once daily for 14 successive days on the mean fold change of the, mRNA relative expression of regenerative markers (PCNA, Fibronectin, Col1, and MMP9) to internal control gene Gapdh (A–D) and collagen deposition (E,F) of a diabetic wound infected with clinical isolates of *P. Mirabilis* infected with LC587231 in Type 1 diabetic rats. (A) mRNA relative expression of PCNA to internal control gene Gapdh, (B) mRNA relative expression of Fibronectin to internal control gene Gapdh, (C) mRNA relative expression of COL1 to internal control gene Gapdh, (D) mRNA relative expression of MMP9 to internal control gene Gapdh, (E) a photomicrograph of Masson blue staining of: control group (left panel), cefepime-treated group (middle panel), and CFE-treated group (right panel), (F) for the level of the collagen deposition.

2.6. Effect of Topical Application of Either CFE or Cefepime Hydrogel on the Wound Growth Factors Signaling Pathway

The results of the present investigation showed that CFE (topical application) significantly upregulated the mRNA expression of PPAR-α ($p < 0.0001$), PGC1-α ($p < 0.0001$), GLP-1 ($p < 0.05$), GLPr-1 ($p < 0.05$), EPGF-β ($p < 0.001$), EPGFr ($p < 0.0001$), VEGF-β ($p < 0.0001$), and FGF-β ($p < 0.05$) both when compared with the diabetic group or cefepime-treated one. Additionally, cefepime topical application showed upregulation of those mRNA expression...
factors that matched that obtained by CFE; both CFE and cefepime showed better effects when compared with controls (Figure 5A–H).

Figure 5. Effect of the hydrogel topical application of cefepime and CFE once daily for 14 successive days on the mean fold change of the mRNA relative expression of growth factors signaling pathway (PPAR-α, PGC1-α, GLP-1, GLPr-1, EGF, EGFr, VEGF, and FGF) to internal control gene Gapdh (A–D) and collagen deposition (E,F) of a diabetic wound infected with P. Mirabilis in Type 1 diabetic rats. (A) mRNA relative expression of PPAR-α to internal control gene Gapdh, (B) mRNA relative expression of PGC1-α to internal control gene Gapdh, (C) mRNA relative expression of GLP-1 to internal control gene Gapdh, (D) mRNA relative expression of GLPr-1 to internal control gene Gapdh, (E) mRNA relative expression of EGF to internal control gene Gapdh, (F) mRNA relative expression of EGF to internal control gene Gapdh, (G) mRNA relative expression of VEGF to internal control gene Gapdh, and (H) mRNA relative expression of FGF to internal control gene Gapdh. **** very distinctive difference; *** Distinctive difference; ** Moderate difference; * Scant difference.

2.7. Effect of CFE and Cefepime on the Wound Oxidative Status

The results of this investigation (Figure 6A–D) have showed that topical application of CFE caused a significant decrease \((p < 0.001)\) in the mean value of the lipid peroxidation marker malondialdehyde (MDA) and a significant increase \((p < 0.001)\) in the mean value of the antioxidant enzyme activity of glutathione peroxidase (GPx), superoxide dismutase (SOD), and common antioxidant enzyme (CAT) either compared with the diabetic group (control) or the cefepime-treated one. Moreover, antibiotic therapy showed a significant increase in the mean value of the diabetic wound antioxidant activity either for GPx \((p < 0.01)\), or CAT, or SOD \((p < 0.05)\). Additionally, there was a significant decrease in the mean value of lipid peroxidation markers MDA \((p < 0.01)\) when compared with the diabetic group (Figure 6A–D).
Figure 6. Effect of the hydrogel topical application of cefepime and CFE once daily for 14 successive days on the mean value of the oxidative status of the diabetic wound infected with *P. Mirabilis* in Type 1 diabetic rats (A–D). (A) lipid peroxidation marker (MDA nmol/mg), (B) GPx ng/mg, (C) CAT ng/mg, (D) SOD U/mg. *** Distinctive difference; ** Moderate difference; * Scant difference.

2.8. Effect of CFE and Cefipime on the Expression of Wound Inflammatory and Anti-Inflammatory Markers

Topical application of CFE on induced diabetic wounds showed a significant downregulation in the mean fold change of the mRNA expression of the inflammatory biomarkers (*p* < 0.001) MCP1, TNF-α, NFKβ, IL-1β, and IL-8, as well as a significant (*p* < 0.001) upregulation in the mean fold change of the mRNA expression of anti-inflammatory markers such as IL-10 and IL-4, and a pro-inflammatory one, TGF-β, when compared to the diabetic group as well as for the cefepime-treated group for all the aforementioned markers, with the exceptions of IL-8 and TGF-β, which appeared not affected. Interestingly, CFE topical application showed significant (*p* < 0.001) improvements in the mRNA expression of the anti-inflammatory markers IL-10 and IL-4 when compared to the cefepime-treated group (Figure 7A–H).
Figure 7. Effect of the hydrogel topical application of cefepime and CFE once daily for 14 successive days on the mean fold change of the mRNA relative expression of inflammatory and anti-inflammatory markers to internal control gene Gapdh of the diabetic wound infected with P. Mirabilis in type 1 diabetic rats (A–H). (A) mRNA relative expression of MCP1 to internal control gene Gapdh, (B) mRNA relative expression of TNF-α to internal control gene Gapdh, (C) mRNA relative expression of TGF-β to internal control gene Gapdh, (D) mRNA relative expression of NF-κβ to internal control gene Gapdh, (E) mRNA relative expression of IL-1β to internal control gene Gapdh, (F) mRNA relative expression of IL-8 to internal control gene Gapdh, (G) mRNA relative expression of IL-4 to internal control gene Gapdh, and (H) mRNA relative expression of IL-10 to internal control gene Gapdh. *** Distinctive difference; ** Moderate difference.
2.9. Effect of CFE and Cefepime on the Wound Apoptotic Signaling Pathway

The results of the current work illustrated that CFE topically treated diabetic wounds elicited a significant downregulation in the mean value relative mRNA expression of the pro-apoptotic markers FAS \( (p < 0.05) \), FAS-L \( (p < 0.05) \), BAX \( (p < 0.05) \), BAX/BCL-2 \( (p < 0.05) \), Caspase-3 \( (p < 0.05) \), P53 \( (p < 0.05) \), and P38 \( (p < 0.05) \), as well as a significant \( (p < 0.001) \) upregulation in the mean fold change of the relative mRNA expression of the antiapoptotic one BCL-2 (Figure 8A–H).

Figure 8. Effect of the hydrogel topical application of cefepime and CEF once daily for 14 successive days on the mean fold change of the mRNA relative expression of the apoptosis signaling pathway (FAS, FAS-L, BAX, BCL-2, BAX/BCL-2, Caspase-3, P53, and P38) to internal control gene Gapdh (A–D) and collagen deposition (E,F) of diabetic wound infected with clinical isolates of P. Mirabilis infected LC587231 in type 1 diabetic rats. (A) mRNA relative expression of FAS to internal control gene Gapdh, (B) mRNA relative expression of FAS-L to internal control gene Gapdh, (C) mRNA relative expression of BAX to internal control gene Gapdh, (D) mRNA relative expression of BCL-2 to internal control gene Gapdh, (E) mRNA relative expression of BAX/BCL-2 to internal control gene Gapdh, (F) mRNA relative expression of Caspase-3 to internal control gene Gapdh, (G) mRNA relative expression of P53 to internal control gene Gapdh, and (H) mRNA relative expression of P38 to internal control gene Gapdh. *** Distinctive difference; ** Moderate difference; * Scant difference.

2.10. Effect of CFE and Cefepime on the Histopathological Picture of Type 1 Diabetic Wound

Histopathological examination of the hematoxylin and eosin (H&E) stained section of the diabetic, infected, non-treated wound showed congested blood vessels, massive leukocytic infiltration, and appearance of vascular granulation tissue (Figure 9A,D,G). However, the histomorphic picture of the cefepime-treated diabetic wound indicated moderate leukocytic infiltration with the appearance of the epidermal pads, hair follicle, and collagen that indicated the common signs of wound healing (Figure 9B,E,H). On the other hand, histomorphological examination of CFE-treated diabetic wounds illustrated a mild inflammatory reaction, appearance of a moderate number of the fibroblast, along with granulation tissue, development of epidermal pads, increasing both epidermal and
dermal thickness, and restoration of both the hair follicles and the sebaceous gland that indicated an advanced regenerative state of the damaged diabetic skin (Figure 9C,F,I).

**Figure 9.** Effect of the hydrogel topical application of cefepime and CFE for successful 14 days on the histopathological changes of the clinical isolates of *P. mirabilis*-infected diabetic wound in rats (A–I). (A) a photomicrograph of the diabetic infected untreated wound showing sloughed epidermal layer (black arrow), degenerated sebaceous gland (black circle), and smooth muscle (yellow arrow) H&E ×100, (B) a photomicrograph of cefepime-treated diabetic infected wound showing indefinite thin epidermal layer (black arrow), few degenerated sebaceous glands (black circle) and hair follicles (blue circle), and smooth muscle (yellow arrow) H&E, ×100, (C) a photomicrograph of clove ethanolic-extract treated diabetic infected wound showing thick well defined multicellular epidermal layer (black arrow), numerous regenerated hair follicles (blue arrow) and sebaceous glands (black circle), and well defined smooth muscle fiber (yellow arrow), H&E, ×100, (D) a photomicrograph of diabetic infected untreated wound showing narrow dermal layer with few depositions of collagen and granulation tissue (black line) and a severely degenerated muscular layer (black circle), H&E, ×100, (E) a photomicrograph of diabetic cefepime-treated diabetic infected wound showing moderate; dermal thickness (black line) and muscular degeneration (black circle), H&E, ×100, (F) a photomicrograph of clove ethanolic extract-treated diabetic wound showing heavy deposition of both collagen and granulation tissue with increasing dermal thickness (black line) and unaffected muscular tissue (black circle), H&E, ×100, (G) a photomicrograph of untreated diabetic infected wound showing severely congested blood vessels (black arrow), degenerated sebaceous glands (black circle), and abundant leukocytic infiltration with few fibroblastic ones (red circle), H&E, ×100, (H) a photomicrograph of cefepime-treated diabetic wound showing moderate blood vessel congestion (black arrow), leukocytic infiltration (red circle), and few sebaceous glands, H&E, ×100, (I) a photomicrograph of clove ethanolic extract-treated diabetic infected wound showing mild leukocytic infiltration (red circle), blood vessel congestion (black arrow), and numerous sebaceous glands with obvious filtration of fibroblast cells (yellow arrow), H&E, ×100.
3. Discussion

DFUs are most serious diabetic complications in Egypt; their infectious bacteria were found to develop resistant variants which make their treatment difficult [37]. This has resulted in interest in isolation and characterization of MDR bacteria infecting diabetic feet. In this study, about 64 bacterial isolates were isolated from DF biopsy; the MDR bacterial isolates 9, 11, 16, and 32 were identified by a Vitek-2 system as belonging to Morganella morgani, Proteus mirabilis, Serratia fonticola, and Escherichia coli, respectively. Many previous studies have identified clinical bacteria by the Vitek-2 system [21]. P. mirabilis showed the highest MAR index and was resistant to eight antibiotics out of the thirteen used. It was resistant to ampicillin, ampicillin/sulbactam, aztreonam, cefazoline, cefepime, ceftriaxone, tetracycline, and nitrofurantoin. This showed that the bacterium P. mirabilis was of interest and indicated a full characterization of this pathogen, its identification by 16S rRNA was done and confirmed a successful biochemical identification [16]. It was stored in Gene Bank under accession number LC5877231 and was designated P. mirabilis LC587231 (P. mirabilis).

The antibiotic cepfime is the one of choice in Egypt as it is available in the Egyptian market. P. mirabilis was resistant to cepfime discs containing 30 μg/mL and many infectious bacteria resist these antibiotics at lower concentrations [38]. The DF pathogen P. mirabilis was grown in different concentrations of the antibiotic cepfime and the MIC and MBC were shown to be 50 μg/mL, and 60 μg/mL, respectively. The P. mirabilis pathogen was resistant to 30 μg/cefepime disc and started to be inhibited at ≥50 μg/mL. This would be due to lower concentrations of the antibiotic cepfime not saturating the specific site(s) receptors of bacterial cell membrane and the higher concentrations might saturate these receptors and in turn interfere with bacterial cell wall synthesis by covalently binding enzymes, leading to bacterial inhibition [39,40].

CFE inhibited P. mirabilis distinctively in vitro and this concurs with latter published results [31]. In view of bioactive compounds elucidated by GC-Mass spectroscopy, almost all of them were reported to inhibit bacterial pathogens by different mechanisms of action. Eugenol, esters (4-alkyl-3-methoxy-phenyl acetate, 3-methyl-2-methoxy-4-(2-propenyl) phenyl butanate), and α-sitosterol are, in general, positively charged and more hydrophobic and this leads to electrostatic interactions with bacterial cellular components, which could lose electrolytes, resulting in cell death [41]. Other heterocyclic compounds such as caryophyllenes and hexahydronaphthalene appeared to herein inhibit pathogenic bacteria as they can interact either as electrophiles or nucleophiles of the cells, leading to inhibition of DNA synthesis, which causes cell death [11]. Finally, the bicyclic alcohol makes an unsuitable environment in which bacteria cannot grow [11].

Several types of proteins were responsible for wound healing such as MMP3, MMP9, collagen, and fibronectin that are secreted from both keratinocytes and fibroblasts [42]. The present investigation revealed that the topical application of CFE elicited a significant improvement in wound size and wound index in comparison to both the antibiotic-treated group and control one [43]. On the other hand, the CFE-treated group showed a significant upregulation in the mRNA expression of the wound healing markers Coli-1, MMP-9, and fibronectin that go hand in hand with Galehldari et al. [44]. The above-mentioned data indicated an active wound repairing mechanism, since the MMP9 activated the keratinocytes’ migration and secretion of MMP3 is considered the most essential element for wound closure [45]. Moreover, one of the most recorded diabetic drawbacks is peripheral neuropathy and angiopathy that retard diabetic wound healing via interfering with wound peripheral circulation, thus, depriving the fibroblasts and the keratinocytes of the essential nutrient for their growth and proliferation [46]. The results of the present study showed that the topical application of CFE hydrogel induced a marked upregulation in the relative expression of the growth factors related to both angiogenesis, keratinocytes, fibroblast growth, and proliferation, which could be attributed to the increased expression of the glucagon-like peptides and their receptors, thus potentiating secretion of the growth factors such as vascular endothelial growth factors (VEGF) that improve wound microcirculation [47], epidermal growth factor (EGF) [48], and fibroblast growth factors [49]. On the other hand,
several previous reports illustrated the role of peroxisome proliferator-activated receptors alpha (PPAR-α) and their co-activators (PGC1-α) in the wound healing process [50–52].

The findings of the current work are in accordance with previous notions, as CFE application upregulated the expression of the PPAR-α and its coactivator PGC1-α. Besides, the hyperglycemic state that is experienced in Type 1 diabetes leads to an increase in advanced glycation products (AGP), reactive oxygen species (ROS), and reactive nitrogen species (RNS) that elicit an imbalance in the oxidant/antioxidant activity [53]. The findings of the current investigation were in the same line with the aforementioned consequences, illustrated by the marked increase in the lipid peroxidation marker MDA and decrease in the antioxidant activity for GPx, SOD, and CAT activity. Furthermore, the increased AGP, ROS, and NRS activates TNFα, inducing cleavage for the TNF superfamily secreted from the inflammatory cells [54,55], and stimulating NF-κβ, which impairs both angiogenesis and wound closure [56].

Interestingly, the results of the present investigation were in line with the previous notion since the infected diabetic wound showed a marked upregulation in the inflammatory marker mRNA expression of IL-8, IL-1β, and TNF-α as a response to the wound oxidative state that discussed the retarding of diabetic wound healing. However, topical application of the CFE on the diabetic infected wound improved the cellular events that were shown with the enhanced wound oxidative microenvironment, noticeably through downregulation of the inflammatory markers TNF-α, IL-1β, and IL-8, with a marked upregulation in the anti-inflammatory markers IL-4 and IL-10 [57]. The anti-inflammatory microenvironment created with topical application of CFE could be referred to by the bioactive compounds that are present in CFE [58,59], which inhibit MAPkinases (p38 pathway) and stimulate IL-4 and IL-10 anti-inflammatory cytokines [60]; likewise, evoked marked upregulation in the Nrf-2 that inhibits keap1 protein expression leads to induction of the AMPK/GSK3β/ERK pathway that downregulates expression of the NF-κβ-65, improving the wound microenvironment and reducing further tissue damage. The previous reports were in fulfillment of the results of the current study, as the diabetic infected wound showed upregulation in the mRNA expression of MCP-1 that was downregulated in the CFE-treated group, followed by the antibiotic-treated one, which could explain the superior healing potency in the CFE group when compared with the others [61]. On the same line, TGF-β is considered one of the essential wound healing elements that is implicated in migration and differentiation of the fibroblast and endothelial cells, and improves wound healing, collagen, matrix metalloproteinase deposition, and angiogenesis [61].

The results employed herein showed that CFE-treated group showed a marked upregulation in the wound expression of TGF-β1; the retardation in the diabetic wound could be owed to the hyperglycemic wound oxidative stress that manifested with increasing AGE, ROS, and RNS, which stimulated mitogen-activated protein kinase/inflammatory/apoptotic pathways [62]. The CFE hydrogel topical application improved the wound healing, resulting in downregulation of the MAPK, apoptotic markers’ expression, and upregulation of the antiapoptotic marker BCL- mRNA expression, which was in line with Medicherla et al. [63], who reported that inhibition of the MAPK (P38) improves diabetic wound healing and re-epithelialization via modulation of inflammatory and apoptotic signaling pathways. These data evidenced that CFE comprised bioactive compounds that abolished the diabetic cytotoxic effect on the keratinocytes and fibroblast.

In regard to the total bacterial count and the coliform count, they were significantly reduced in both the CFE-treated group and the cefepime-treated one when compared with the diabetic infected group (control), which might reveal that CFE contains antibacterial bioactive compounds [64].

Finally, the results of the present work showed that the use of CFE almost matched the use of the cefepime antibiotic concerning infected diabetic wound healing, which might be ascribed to the cytotoxicity of the antibiotics to both fibroblasts and keratinocytes, reducing the proliferative capacity, collagen, fibronectin, and wound matrix protein deposition, forming either less tensile granulation tissue or scar formation [65–68]. However, the
antibiotics could improve diabetic wound healing via controlling the bacterial infection, increasing the innate immune cells infiltration, but unfortunately, they negatively impacted the fibroblast and keratinocytes’ viability, proliferative capacity, and, consequently, the matrix proteins’ formation and re-epithelialization that was shown with the reduced expression of the PCNA and the upstream expression of the apoptotic pathway. Such limitations could be avoided with *Syzygium aromaticum* extract application that comprises both antibacterial activity and wound remodeling capabilities, without neither fibroblast nor keratinocytes cytotoxicity.

Further work will be necessary to investigate the effect of combinations of the antibiotic cefepime and CFE on the inhibition of this *P. mirabilis* and other MDR bacteria in vitro and in vivo.

### 4. Materials and Methods

#### 4.1. Chemicals, Drugs, and Plants

Chemicals for diabetes induction (STZ, citric acid, sodium citrate), and hydrogel formation (sodium metabisulfite, sodium methylparaben, sodium propylparaben, and carbopol 934) were purchased from Sigma Aldrich (USA). Cefepime antibiotics were provided from Pharco Pharmaica Company, Cairo, Egypt. The plant clove (*S. aromaticum*) was obtained from a herbal market at Mansoura city (100 km North Cairo, Egypt), identified morphologically in the Department of Botany Faculty of Science Mansoura University, Egypt, and the plant name was checked with [http://www.theplantlist.org](http://www.theplantlist.org) (accessed on 2 March 2022) and [http://ipni.org/urn:lsid:ipni.org:names:601421-1](http://ipni.org/urn:lsid:ipni.org:names:601421-1) (accessed on 2 March 2022). Additionally, the clove is listed in the European pharmacopeia (EMA/HMPC/475451/2020 & EMA/HMPC/534924/2010 & EMA/HMPC/534946/2010 & EMA/HMPC/534948/2010).

#### 4.2. Pus Sample Collection and Bacterial Identification

A total of forty-seven diabetic patients’ pus samples were collected from Zagazig University hospital (Zagazig, 80 km North Cairo, Egypt), with the patient’s written informed consent. Pus samples were transported to the Laboratory of Microbiology, Faculty of Science, Zagazig University in a sterile containers within one hour for microbiological analysis. The bacterial isolation from each pus sample was carried out on both MacConkey agar (Oxoid) and blood agar (Oxoid). A total of about 64 bacterial isolates were obtained. All of these isolates were assayed for antibiotic sensitivity using 13 antibiotics that assimilate 7 antibiotic types such as cephalosporines, polymexins, penicillins, fluroquinolones, aminoglycosides, macrolides, and sulphonamides [19,20,69]. Results were taken according to CLSI [70]. Multiple antibiotic resistance index (MAR) was calculated using the following formula: MAR index = number of antibiotics to which the bacterial isolate were resistant/Total number of antibiotics investigated [11].

The MDR bacteria obtained were the isolates DFU 9, 11, 16, and 32. They were identified biochemically using the Vitek-2 system [71]. The bacterial strain DFU 11, with the highest MAR index, was subjected to molecular identification for full characterization and to confirm its identification by fingerprinting of the sequence of 16S rRNA gene. Therefore, its DNA was extracted. Then, its 16S rRNA gene was amplified by polymerase chain reaction using universal primers: forward primer; 5'-AGAGTTTGATCCTGGCTCAG-3' and reverse primer, 3'-GGTTACCTTGTTACGATT-5'. The PCR was carried out in a GenAmp PCR system 9600 thermocycler (Perkin Elmer Company, NJ, USA) as described previously [72]. The PCR product was electrophoresed using agarose gel (0.7%) (Gomhuria Company, Egypt). The 16S rRNA gene band that appeared at 1500 bp was cut by Gene purification kit (Promega Corporation, Madison, WI, USA) and the nucleotide sequence of 16S rRNA gene of the strain DFU 11 was sequenced by using a 3130x DNA sequencer (Genetic Analyser, Hitachi, Ibasaki, Japan). The sequence was submitted to the Gene Bank at [http://BLAST.NCBI.NLM.NE].gov (accessed on 2 March 2022) and by using the Basic Local Alignment Search Tool Program. A cluster analysis and phylogenetic tree were constructed (Supplement Figure S1). It was shown that the bacterial isolate DFU 11
showed similarity to the *Proteus mirabilis* cluster by >99.6% and consequently, an accession number LC587231 was given to the strain DFU 11 and was identified as belonging to *Proteus mirabilis*, and designated *P. mirabilis* LC587231 (*P. mirabilis*).

4.3. Preparation of the Clove Flower Extract CFE and Phytochemical Screening

CFE was prepared as described previously [73,74]. Briefly, 500 gm of clove flower buds were cleaned from the impurities and washed by distilled water, then dried in a hot air oven (Alexandria Co., Alexandria, Egypt) for 24 h at 40 °C. The flowers were then ground to powdered form using a clean sterile mortar and pestle (Moulinex, Cairo, Egypt) and packed in an airtight plastic container until used. About 10 g aliquots of the powdered clove flower buds were extracted with 1000 mL ethanol by maceration, then filtered through a Buchner funnel with Whatman filter paper number 3, then evaporated under reduced pressure to dryness at 45 °C. A stock preparation (1 g/50 mL) of CFE was suspended in 1% DMSO and sterilized by Milipore filtration (0.45 µm, Amicon). The plant phytochemical screening was done with GC-Mass [29]. A direct capillary column TG-5MS (30 m × 0.25 mm × 0.25 µm thickness) was used. About 3 µL of CFE was injected automatically to the equipment using an Auto sampler AS3000 coupled with GC in the split mode. Then the instrumental analysis was carried out as described previously [11]. The components were identified by comparison of their retention times and mass spectra with those of Wiley 09 and NIST 11 mass spectra databases [11].

4.4. Antibacterial Activity of CFE against MDR *P. mirabilis*

Muller-Hinton agar plates (Oxoid) were prepared and seeded with log phase cells of *P. mirabilis* (10^5 CFU/mL). Then, 5 mm wells were created with a sterile crok pourer and loaded with 100 µL of CFE. Finally, the plates were incubated for 24 h at 37 °C and the inhibition zones were measured in millimeters. The antibacterial activity was done in triplicates to confirm the antibacterial activity [11].

4.5. (MICs) of Both CFE and the Antibiotic Cefepime

MIC of CFE was determined as described previously [28]. Briefly, serial two-fold dilutions were made from 1 mL CFE in sterile test tubes containing brain heart infusion broth (BHI, Oxoid). The tubes were inoculated with 2 × 10^5 CFU/mL of *P. mirabilis*, and were then incubated at 37 °C for 48 h. The last dilution with no visible growth (no turbidity) was defined as the MIC. From the last two tubes giving growth inhibition, 100 µL was streaked onto BHI agar and incubated at 37 °C for 24 h. The last concentration that showed no growth was defined as the minimum concentration that killed bacterial cells (MBC).

MIC of the antibiotic cefepime was determined according to Abdel-Shafi et al. [39]. Serial two-fold dilutions of the antibiotic cefepime (1 g/50 mL, Pharco, Pharmacia) were made in sterilized distilled water (100 µL, Eppendorf) (65) and were added to brain heart infusion plates, and then the plates were inoculated with about 2 × 10^5 CFU/mL of actively growing cells of *P. mirabilis* and incubated at 37 °C for 24 h. MIC and MBC were determined as described previously [11,28].

4.6. CFE and Cefepime Hydrogel Preparation

The hydrogel was used as a vehicle for topical application of either CFE or the antibiotic cefepime that was formed as described previously [75–77]. In a sterile packed jar containing 50 mL sterile distilled water, sodium methylparaben, sodium propylparaben and sodium metabisulfite (about 4 g of each) were dissolved. Then, carbopol was added gradually with stirring slowly thoroughly, with addition of either CFE or the antibiotic cefepime until a swollen gel was developed. The whole volume was completed by distilled water to create a 100 g gel that contained 20 mg/mL of either CFE or the antibiotic cefepime. The jar containing the prepared gel was covered with a screw-capped plastic lid and was left for 24 h at room temperature to allow components to equilibrate; then, they were kept in refrigerator until used.
4.7. Experimental Animals and Ethical Declaration

The Zagazig University Animal Care Board approved the experiments carried on animals (*Rattus norvegicus*). Forty-five male adult mature albino rats (*Rattus norvegicus*) 8–10 weeks old and weighing 250–300 gm were purchased from Lab. Animal House, Faculty of Veterinary Medicine Zagazig University, Zagazig, Egypt. Rats were housed separately in a polypropylene rat cage with standard housing conditions: relative humidity 45–50%, 12 h light/dark cycles, and temperature 22 ± 2 °C. Rats were fed on a standard pelleted diet *ad libitum* with free access to water throughout the experimental period. Before any experimental procedures, lab animals were left one week for acclimatization.

4.8. Experimental Design

Forty-five male adult albino rats (*Rattus norvegicus*) were intraperitoneally injected with freshly prepared STZ in 0.1 M citrate buffer at a dose of about 65 mg/kg body weight for Type 1 diabetes induction as described previously [78]. Seven days post STZ injection, the Type 1 diabetes onset was assessed via measuring fasting blood glucose using a digital glucometer (U-Right, Korea). Rats that had blood glucose levels above 350 mg/dL were enrolled in the experiment. Then, wounds were done in accordance with Muhammad et al. [79]. In brief, rats were anesthetized with an intraperitoneal injection of ketamine 90 mg/kg and xylazine 10 mg/kg. Dorsal fur was clipped with an electrical hair clipper (Alexandria Company, Egypt), the skin was disinfected with 70% ethanol, a full-thickness round wound excision 10 mm in diameter and 2 mm in thickness was created with Biopsy Punch (Gomhuria Company, Egypt), and then infected with $2 \times 10^8$ CFU/mL of the *P. mirabilis* bacterium. After two days of infection, the rats were divided into three groups each of 15 rats. In group 1, the diabetic infected wounds of this group were treated with cefepime hydrogel. In group 2, the diabetic infected wounds were treated with CFE hydrogel; in group 3, diabetic infected wounds were treated with a hydrogel only (control). The treatment of diabetic wounds with hydrogels mentioned above were carried out one time every day throughout two weeks. Rats were kept separately in polypropylene cages to avoid fighting and wound biting. To assess the wound healing capacity, wound diameter and wound index were evaluated every 3 days throughout 18 days. At the end of the experiment, blood was collected from retro-orbital eye saphenous. Then, rats were killed and the skin of the wound was excised and divided into four parts; one part was collected on 10% formalin neutral buffer for histopathological examination, the second part was collected in peptone water for determining wound microbial load, the third part was stored at −20 °C for oxidant/antioxidant activity, and the fourth part, being 24 h of diabetic skin wound, was collected in 1 mL of quiazel (Qiagen, Germany) for total RNA extraction for RT-qPCR to quantify relative diabetic wound gene expression.

4.9. Measuring Glycemic Parameters and Oxidant/Antioxidant Activity

Blood glucose was measured 7 days post-STZ injection with a digital glucometer (U-Right, Korea). Insulin was measured in serum with sandwich ELISA Kit (SunRedBio, China) as described previously [80]. Lipid peroxidation marker Malondialdehyde (MDA) and antioxidant enzyme glutathione peroxidase (GPx), common antioxidant enzyme (CAT), and superoxide dismutase (SOD) were locally measured with a sandwich ELISA kit (SunRedBio, China) according to the method developed by Zhang et al. [81].

4.10. Measuring Wound Diameter and Wound Index

Wound diameter was measured with a measuring scale per centimeter and the wound index was calculated with the following equation [wound diameter of each time set point/initial wound diameter] according to Mendes et al. [37].

4.11. RT-qPCR for Wound Gene Expression

Total RNA was extracted from 50 mg skin tissue with 1 mL Quiazel (QIAGEN, Germany) according to the manufacturer’s instruction. The extracted total RNA was measured
with a NanoDrop® ND-1000 UV-Vis Spectrophotometer (Thermo Scientific, Waltham, MA, USA) at wavelengths of 260 and 280 nm. The ratio of OD 260/280 was calculated to determine the quality of the extracted RNA; ones that were accepted for gene expression were located in the value between 1.8–2. cDNA was synthesized from 1 µg with a high capacity reverse transcriptase kit (Applied Biosystem, Foster City, CA, USA) in a final reaction volume of 20 µL (10 µL master mix and 10 µL RNA sample containing 1 µg RNA). cDNA was diluted 1:10, stored in aliquots at −20 °C for qPCR reaction. The qPCR was done by a real-time thermal cycler, Rotor-Gene Q 2 plex (Qiagen, Germany), as described previously [82]. Briefly, starting with a final volume reaction of 20 µL, using TOPreal syber-Green (Enzynomics, Korea) 10 µL, 1 µL of each forward and reverse primers synthesized by Sangon Biotech (Beijing, China) (Table 4), 1 µL of 1:10 diluted cDNA, and up to 20 µL of nuclease-free water were added, with cycling conditions of initial denaturation 95 °C for 10 min, 40 cycles of denaturation at 95 °C for 10 s, annealing at 60 °C for 15 s, and extension 72 for 15 s, and a melt curve analysis was performed. The gene expression was measured as relative fold change to an internal control reference gene (Gapdh) as described previously [83]. Briefly, Δct was calculated as the ct difference between the target gene and reference gene, then, ∆∆ct was calculated as the difference between Δct of the sample and the average Δct of the control; finally, fold gene of the gene expression was calculated as $2^{-\Delta\Delta ct}$.

**Table 4.** Primers sequence used and their sequences.

| Primer | Forward Primer (5′–3′) | Reverse Primer (5′–3′) | Size | Accession No. |
|--------|------------------------|------------------------|------|---------------|
| PCNA   | ATCTAGACGTGCAACTCCG    | GCTGCACTAAGGAGACGTGA  | 173  | NM_022381.3   |
| Mmp9   | GATCCCCAGAGGCTACTCG    | GTTGGAAACTCAAGGCC    | 132  | NM_031055.2   |
| Collagen | GCAATGCTAATTCGCCAC    | CAGCAGAGCCCACAAC    | 176  | NM_053304.1   |
| Fibronectin | GAGATCCCTCTCCAGAGAGT | GGGTGGAAAGTGAACAGC    | 188  | NM_019453.2   |
| NF-κB1 | CCAGTCTCAACAGATGGC    | CTTTGCAGCACCACAGT    | 177  | NM_00276711.1 |
| TNF-α  | GCCTTCGGAATCCCAGTGA   | GGGAAACAGCAGGAGATC   | 164  | NM_012675.3   |
| IL-10  | GCTCACGACTGCTATTTGC   | TTTTCACCCGAGGAAATG   | 76   | NM_012854.2   |
| IL-8   | ACAGGAGGCTGATTTGTC    | ATCCACAGCGATTTCCAG   | 70   | NM_019310.1   |
| IL-4   | CGTATGATCACTTCCCGTCTT | GTGATTTGACAGGGCTGAC  | 88   | NM_201270.1   |
| IL-1β  | GAGTCTCCACATCTTCCCA   | TCCTGGGGAAGGATTAGGA  | 158  | NM_031512.2   |
| MCP-1  | TAGCATCCACGTGCTCTC    | CAGCGCATCTATGGGATCA  | 94   | NM_013510.3   |
| TGF-β1 | AGGCTTATCCACATCCAC    | CACCTGATAGCATGAGGC   | 168  | NM_021578.2   |
| IL-1β  | GAGTCTCAGCATCTTCCCA   | TCCTGGGGAAGGATTAGGA  | 158  | NM_031512.2   |
| Gapdh  | GCCATCTGCTGTGAGTC     | GGTAAACAGGGCTCTAGA   | 91   | NM_017008.4   |
| GLP1   | CCACCTCTCTCAGTCCAGT   | GGTCTTCCCTCTTGTCCT   | 128  | NM_012707.2   |
| GLPr1  | CTGATGACATGAGAGGGGAC  | AGGAGCATGGCTTGGTAG   | 128  | NM_172091.2   |
| EGF-β1r| GGGCATGATGCCAGAGAAC   | GGATCTTTGCCCCATAGCA  | 100  | NM_00139370.1 |
| EGF-β1 | GGTCCACCATTTGGCAAAAC  | CAGGATCTTCTCCAGCAC   | 118  | NM_012842.2   |
| PPAR-α | GTCTCTGTTGTATCCCTTG  | TGCATCTCAGAGGAAGCc   | 176  | NM_031962.2   |
| PGC-1α | TTCAAGAGAGCAGTTGGTCTT | GGCGACACACTCTATGTC   | 70   | NM_031347.1   |
| FGF    | GAGGACCTCCATACCAA     | CTGTTCCAGTTCCAGAC    | 222  | NM_019305.2   |
| VEGF   | GATCCATTTGCCGAAGATC   | TCTTCTCTTCTTTGGTCTGAT | 83   | NM_053549.1   |
| Bax    | CGAATTTGGGTAAGAAGGA   | CAAACATGCGACGCGAC    | 109  | NM_017059.2   |
| Bel-2  | GACTGATACCTGGAAAGGCA  | CTGACGACTTGTCCTAGCAC  | 135  | NM_016993.1   |
| Fas    | GAGGTGGTGTGAGGAGCA    | AGTWGGTGGACACCTTCTG  | 128  | NM_139194.2   |
| FasL   | CACCAACCAAGGCTGTAGATCA | TACTGACGATCAAAGGAGTTCT | 172  | NM_012908.1   |
| P38    | CGGCGATTCTCTTCTTACAGA | GGAGGGCGTGTTCATACAC  | 214  | NM_013020.2   |
| P53    | CATGAGGCTTGCTTGTTGCTT | GATTTCTCTCACCGAGATA  | 67   | NM_030989.5   |
| Casp-3 | GAGACAGCAGTTCGGAACGAGT | GGGCGAAGTGACTGGTGATG  | 147  | NM_012922.2   |
| 16s rRNA | AGAGTTCTGATTCTGCTCAG   | CTACGGCTACTCTGTTACGA | 1507 | NM_043997.1   |

4.12. Determination of the Wound Total Bacterial and Coliform Count

The total bacterial and coliform count were carried out according to Xu et al. [84]. Briefly, 1 gm of diabetic wound skin was macerated in 9 mL peptone water and serially diluted with ten-fold dilution. From each dilution, 100 µL was cultured on both nutrient


and McConkey agar (Difco) with the spread plate method and incubated at 37 °C for 24 h. Then, the counting of the colony-forming unit (CFU) for either total bacterial or coliform count were performed in triplicates.

4.13. Histopathological Examination for H&E and Masson Blue

The histopathological procedures were done in accordance with Bancroft and Layton [85]. In brief, at the end of the experiment, the sacrificed skin of the wound area of rats was rapidly removed and collected in 10% formalin neutral buffer then embedded in a paraffin wax block and cut into 4 µm slices, before being mounted on a microscope slides that were used for histological stains. Before any histopathological procedures, the slides were incubated in xylene and passaged in ethanol with different concentrations for rehydration and paraffin wax removal, then the slides were stained with H&E for assessment of wound healing and Masson Trichome for collagen deposition (percentage of collagen deposition to control group was analyzed with Fiji software (http://fiji.sc, accessed on 28 June 2012).

4.14. Data Analysis and Statistics

Statistical analysis was performed by GraphPad Prism 8 software (GraphPad Software Inc., San Diego, CA, USA). Data are expressed as mean ± standard error mean (S.E.M). Statistical comparisons were performed using a one-way analysis of variance (ANOVA) test followed by a post hoc Tukey test. The results indicated a statistical significance when \( p < 0.05 \).

5. Conclusions

It was concluded from this work that in diabetic foot infections, bacteria causing DFU can resist the action of many antibiotics and could cause many complications. CFE was shown to be a promising antibiotic alternative when used in hydrogel topical applications, as it improved the healing of STZ-induced diabetic rat wounds infected with multidrug resistant bacteria; its effect almost matched the one caused by cefepime and was superior in improving wound size, wound index, and certain immunological markers. However, further work will be necessary to investigate the in vitro and in vivo synergistic effect of both CFE and the antibiotic cefepime in combinations.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules27072270/s1. Table S1: Susceptibility of bacterial isolates to different antibiotics; Figure S1: Phylogenetic tree analysis based on 16 s rRNA nucleotide sequence alignment for \( P. \) mirabilis with other related members that possess the best similarity; Figure S2: GC-Mass of the \( Syzygium \) aromaticum ethanolic extract indicating retention time of different identified bioactive compounds; Figure S3: GC-Mass fragmentation pattern of the different identified bioactive compounds from the ethanolic extract of the \( Syzygium \) aromaticum indicating molecular weight (\( m/z \)) of each compound.

Author Contributions: G.E., G.A.-F., G.E.-D. and B.S. designed the research protocol, supervised the whole experiments and reviewed the manuscript; R.A., G.E. and G.E.-D. carried out the experiments of isolation, identification, antibiotic bioassays of the bacterial isolates; T.K., and R.A. carried out the in vivo experiments. All authors have read and agreed to the published version of the manuscript.

Funding: This work was financially supported by grants from the County Council of Västerbotten and Cancer Research Foundation in Northern Sweden (BS).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgments: The authors are indebted to A.H. Moustafa, scholar of Organic Chemistry for construction of the bioactive compounds of CFE.
Conflicts of Interest: The authors declare that they have no competing interest; financial or otherwise.

Sample Availability: Samples of the compounds aren’t available from the authors.

References

1. Core, D.; Ahn, J.; Robert, B.S.; Lewis, B.; Katherine, M.D.; Rasposic, M.; Trapper, D.P.M.; Lalli, A.J.; Dane, K.; Wukich, M.D. The Evaluation and Treatment of Diabetic Foot Ulcers and Diabetic Foot Infections. Foot Ankle Orthop. 2018, 3, 247301141878886. [CrossRef]

2. Williams, D.T.; Hilton, J.R.; Harding, K.G. Diagnosing foot infection in diabetes. in Clinical Infectious Diseases. Clin. Infect. Dis. 2004, 39 (Suppl. 2), S83–S86. [CrossRef] [PubMed]

3. Enan, G. Control of the regrowing bacteriocin resistance variants of Listeria monocytogenes LMG 10470 in Vitro and in Food by nisin-plantaricin UG1 mixture. Biotechnology 2006, 5, 143–147. [CrossRef]

4. Abdel-Shafi, S.; Ouda, S.M.; ElBalat, I.; Enan, G. Characterization and identification of multidrug resistant bacteria from some Egyptian patients. Biotechnology 2013, 12, 65–73. [CrossRef]

5. Enan, G.; Abdel-Shafi, S.; Ouda, S.M.; El-Balat, I. Genetic linkage of the antibiotic resistance ability in the Escherichia coli UR4 strain isolated from urine. J. Med Sci. 2013, 13, 261–268. [CrossRef]

6. Ismaiel, A.A.; Ali, E.A.; Enan, G. Incidence of Listeria in Egyptian meat and dairy samples. Food Sci. Biotechnol. 2014, 234, 179–181. [CrossRef] [PubMed]

7. El-Sayed, T.; Atef, D.; Amer, M.; Mahdy, A.; Enan, G. Molecular characterization and inhibition by natural agents of multidrug resistant Candida strains causing vaginal candidiasis. Res. J. Med Sci. 2015, 9, 1–7.

8. Osman, A.; El-Didamony, G.; Sitohy, M.; Khalifa, M.; Enan, G. Soybean glycinin basic subunit inhibits methicillin-resistant-vancomycin intermediate Staphylococcus aureus (MRSA-VISA) in vitro. Int. J. Appl. Res. Nat. Prod. 2016, 9, 17–26.

9. Saltoglu, N.; Ergonul, O.; Tulek, N.; Yemisen, M.; Kadanali, A.; Karagoz, G.; Batirel, A.; Ak, O.; Sonmez, C.; Eraksoy, H.; et al. Influence of multidrug resistant organisms on the outcome of diabetic foot infection. Int. J. Infect. Dis. 2018, 70, 10–14. [CrossRef]

10. Enan, F.; Osman, M.E.; Abdel-Haliem, M.E.F.; Abdel-Ghany, S.E. Advanced in microbial and nucleic acids biotechnology. Biomed Res. Int. 2018, 2018, 3102374. [CrossRef] [PubMed]

11. Enan, F.; Al-Mohammadi, A.R.; Mahgoub, S.; Abdel-Shafi, S.; Askar, E.; Ghaly, M.F.; Taha, M.A.; El-Gazzar, N. Inhibition of Staphylococcus aureus LC554891 by Moringa oleifera seed extract either singly or in combination with antibiotics. Molecules 2020, 25, 4583. [CrossRef] [PubMed]

12. Fattah Hamid, S.; Bahadeen Taha, A.; Jamel Abdulwahid, M. Distribution of blaTEM, blaSHV, blaCTX-M, blaOXA, and blaDHA in Proteus mirabilis Isolated from Diabetic Foot Infections in Erbil, Iraq. Cell. Mol. Biol. 2020, 66, 88. [CrossRef]

13. Enan, G.; Al-Mohammadi, A.-R.; El-Didamony, G.; Abdel-Haliem, M.E.F. Antimicrobial activity of Enterococcus faecium NM2 isolated from urine: Purification, characterization and bactericidal action of enterocin NM2. Asian J. Appl. Sci. 2014, 7, 721–734. [CrossRef]

14. Enan, G.; El-Didamony, G.; Mohamed, E.H.; Zakaria, A. Novel antibacterial activity of Enterococcus faecium NM2 isolated from urine of healthy people. Asian J. Appl. Sci. 2014, 7, 66–78. [CrossRef]

15. Ouda, S.M.; Debevere, J.; Enan, G. Purification and biochemical characterization of plantaricin UG1, a bacteriocin produced by Lactobacillas plantarum UG1 isolated from dry sausage. Life Sci. J. 2014, 11, 271–279.

16. Abdel-Shafi, S.; Al-Mohammadi, A.–R.; Negm, S.; Enan, G. Antibacterial activity of Lactobacillas delbreukii subsp. bulgaricus isolated from Zabady. Life Sci. J. 2014, 11, 264–270.

17. Osman, A.; Abdel-Shafi, S.; Al-Mohammadi, A.R.; Kamal, N.; Enan, G.; Sitohy, M. Catifish glycoprotein, a highly powerful safe βnanocomposites as antimicrobial agents. Nanomaterials 2021, 11, 3006. [CrossRef]

18. Sitohy, M.; Al-Mohammadi, A.R.; Osman, A.; Abdel-Shafi, S.; El-Gazzar, N.; Hamdi, S.; Ismail, S.H.; Enan, G. Silver-protein nanocomposites as antimicrobial agents. Nanomaterials 2021, 11, 3006. [CrossRef] [PubMed]

19. Askoura, M.; Saed, N.; Enan, G.; Askora, A. Characterization of polyvalent bacteriophages targeting multidrug-resistant Klebsiella pneumonia with enhanced anti-biofilm activity. Appl. Biochem. Microbiol. 2021, 57, 117–126. [CrossRef]

20. Yan, C.; Gao, N.; Sun, H.; Yin, J.; Lee, P.; Zhou, L.; Fan, X.; Yu, F.S. Targeting Imbalance between IL-1β and IL-1 Receptor Antagonist Ameliorates Delayed Epithelium Wound Healing in Diabetic Mouse Corneas. Am. J. Pathol. 2016, 186, 1466–1480. [CrossRef] [PubMed]

21. Ahmad, J.; Zubair, M.; Malik, A. Plasma adiponectin, IL-6, hsCRP, and TNF-α levels in subject with diabetic foot and their correlation with clinical variables in a North Indian tertiary care hospital. Indian J. Endocrinol. Metab. 2012, 16, 769. [CrossRef] [PubMed]
24. Portou, M.J.; Yu, R.; Baker, D.; Xu, S.; Abraham, D.; Tsui, J. Hyperglycaemia and Ischaemia Impair Wound Healing via Toll-like Receptor 4 Pathway: Activation in vitro and in an Experimental Murine Model. *Eur. J. Vasc. Endovasc. Surg.* 2020, 59, 117–127. [CrossRef] [PubMed]

25. Van Asten, S.A.; Nichols, A.; La Fontaine, J.; Bhavan, K.; Peters, E.J.; Lavery, L.A. The value of inflammatory markers to diagnose and monitor diabetic foot osteomyelitis. *Int. Wound J.* 2017, 14, 40–45. [CrossRef] [PubMed]

26. Pradhan, L.; Nabzdyk, C.; Andersen, N.D.; LoGerfo, F.W.; Veves, A. Inflammation and neuropeptides: The connection in diabetic wound healing. *Expert Rev. Mol. Med.* 2009, 11, e2. [CrossRef]

27. Seyed, M.A.; Ayesh, S. Modern Phytomedicine in Treating Diabetic Foot Ulcer: Progress and Opportunities. In *Diabet Foot Ulcer*; Springer: Singapore, 2021; pp. 281–313. [CrossRef]

28. Faujdar, S.; Bisht, D.; Sharma, A. Antibacterial activity of Syzygium aromaticum (clove) against uropathogens producing ESBL, MBL, and AmpC beta-lactamase: Are we close to getting a new antibacterial agent? *J. Fam. Med. Prim. Care* 2020, 9, 180. [CrossRef]

29. Rodrigues, J.W.; Peyron, S.; Rigou, P.; Chalier, P. Rapid quantification of clove (Syzygium aromaticum) and spearmint (Mentha spicata) essential oils encapsulated in a complex organic matrix using an ATR-FTIR spectroscopic method. *PLoS ONE* 2018, 13, e0207401. [CrossRef]

30. Ghasemian, M.; Owlia, S.; Owlia, M.B. Review of Anti-Inflammatory Herbal Medicines. *Adv. Pharmacol. Sci.* 2016, 2016, 9130979. [CrossRef]

31. Batitha, G.E.-S.; Alkazmi, L.M.; Wasef, L.G.; Beshbishy, A.M.; Nadwa, E.H.; Rashwan, E.K. *Syzygium aromaticum* (myrtaceae): Traditional uses, bioactive chemical constituents, pharmacological and toxicological activities. *Biomolecules* 2020, 10, 202. [CrossRef]

32. Batitha, G.E.-S.; Beshbishy, A.M.; Tayebwa, D.S.; Shaheen, H.M.; Yokoyama, N.; Igarashi, I. Inhibitory effects of *Syzygium aromaticum* and *Camellia sinensis* methanolic extracts on the growth of *Babesia* and *Theileria* parasites. *Ticks Tick-Borne Dis.* 2019, 10, 949–958. [CrossRef]

33. Ma, L.; Liu, J.; Lin, Q.; Gu, Y.; Yu, W. Eugenol protects cells against oxidative stress via Nrf2. *Exp. Ther. Med.* 2020, 21, 2. [CrossRef]

34. loose, M.; Pilger, E.; Wagenlehner, F. Anti-bacterial effects of essential oils against uropathogenic bacteria. *Antibiotics* 2020, 9, 358. [CrossRef] [PubMed]

35. Antoncescue, I.A.; Antoncescu, A.; Miere, F.; Fritea, L.; Teus, D.P.; Pinto, A.L. A rat model of diabetic wound infection for the evaluation of topical antimicrobial therapies. *Comp. Med. Am. Assoc. Lab. Anim. Sci.* 2021, 10, 1390. [CrossRef] [PubMed]

36. Antonescu, A.-I.; Miere, F.; Fritea, L.; Ganea, M.; Zdrinca, M.; Dobjanschi, L.; Antonescu, A.; Vicas, S.I.; Bodog, F.; Sindhu, R.K.; et al. Perspectives on the combined effects of *Ocimum basilicum* and *Trifolium pratense* extracts. *Processes* 2021, 9, 2096. [CrossRef]

37. Mendes, J.J.; Leandro, C.I.; Bonaparte, D.P.; Pinto, A.L. A rat model of diabetic wound infection for the evaluation of topical antimicrobial therapies. *Comp. Med. Am. Assoc. Lab. Anim. Sci.* 2012, 32, 37–48.

38. Gullberg, E.; Cao, S.; Berg, O.G.; Ilback, C.; Sandgren, L.; Hughes, D.; Andersson, D.I. Selection of resistant bacteria at very low antibiotic concentrations. *PLoS Pathogens* 2011, 7, 1002158. [CrossRef] [PubMed]

39. Nguyen, H.M.; Shier, K.L.; Graber, G.J. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae. *J. Antimicrob. Chemother.* 2014, 69, 871–880. [CrossRef]

40. Ben-Asher, O.; Uyttendaele, M.; Debevere, J. Antibacterial activity of Lactobacillus plantarum UG1: Characterization, production and bactericidal action of plantaricin UG1. *Int. J. Food Microbiol.* 1996, 30, 189–215. [CrossRef]

41. Abdel-Shafi, S.; Enan, G.; Osman, A.; Kamal, N.; Sitohy, M. Characterization and antibacterial activity of both 7S and 11S globulins isolated from cowpea seed protein. *Molecules* 2019, 24, 1082. [CrossRef]

42. Sautter, N.B.; Delaney, K.L.; Hausman, F.A.; Trune, D.R. Tissue remodeling in the acute otitis media mouse model. *Int. J. Pediatric Otorhinolaryngol.* 2011, 75, 1368–1371. [CrossRef]

43. Alam, P.; Ansari, M.J.; Anwer, M.K.; Raish, M.; Kamal, Y.K.; Shakeel, F. Wound healing effects of nanoemulsion containing clove essential oil. *Artif. Cells Nanomed. Biotechnol.* 2017, 45, 591–597. [CrossRef]

44. Galebhardi, H.; Negahdari, S.; Kesmati, M.; Rezaie, A.; Shariati, G. Effect of the herbal mixture composed of Aloe Vera, Henna, Adiantum capillus-veneris, and Myrrha on wound healing in streptozotocin-induced diabetic rats. *Diabetes Metab. Clin. Exp.* 2012, 1279–1286. [CrossRef]

45. Buteau, J.; Foisy, S.; Joly, E.; Prentki, M. Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epididymal growth factor receptor. *Diabetes* 2003, 52, 124–132. [CrossRef] [PubMed]
49. Kim, J.H.; Lee, G.Y.; Maeng, H.J.; Kim, H.; Bae, J.H.; Kim, K.M.; Lim, S. Effects of glucagon-like peptide-1 analogue and fibroblast growth factor 21 combination on the atherosclerosis-related process in a type 2 diabetes mouse model. *Endocrinol. Metab. 2021*, 36, 157–170. [CrossRef] [PubMed]

50. Ire, G.; Wahl, W.; Michalik, L. Functions of the peroxisome proliferator-activated receptor (PPAR) α and β in skin homeostasis, epithelial repair, and morphogenesis. *J. Investig. Dermatol. Symp. Proc. 2006*, 11, 30–35. [CrossRef]

51. Coll, T.; Barroso, E.; Álvarez-Guardadía, D.; Serrano, L.; Salvadó, L.; Merlos, M.; Palomer, X.; Vázquez-Carrera, M. The role of peroxisome proliferator-activated receptor β/δ on the inflammatory basis of metabolic disease. *PPAR Res. Vol. 2010*, 2010, 368467. [CrossRef]

52. Leask, A. The Contribution of Peroxisome Proliferator–Activated Receptor Gamma to Cutaneous Wound Healing. *Adv. Wound Care. 2013*, 2, 69–73. [CrossRef]

53. Lammers, M.L.; Almeida, M.E.; Vicente-Manzanares, M.; Horwitz, A.F.; Santos, M.E. High glucose-mediated oxidative stress impairs cell migration. *PLoS ONE 2011*, 6, e22865. [CrossRef]

54. Zhou, M.; Zhang, Y.; Ardans, J.A.; Wahl, L.M. Interferon-γ Differentially Regulates Monocyte Matrix Metalloproteinase-1 and -9 through Tumor Necrosis Factor-α and Caspase 8. *J. Biol. Chem. 2003*, 278, 45406–45413. [PubMed]

55. Gill, S.E.; Parks, W.C. Metalloproteinases and their inhibitors: Regulators of wound healing. *Int. J. Biochem. Cell Biol. 2005*, 40, 1334–1347. [CrossRef]

56. Mariotti, A.J.; Rumpf, D.A.H. ‘Chlorhexidine-Induced Changes to Human Gingival Fibroblast Collagen and Non-Collagen Protein Production.’ *J. Periodontol. 1999*, 70, 1443–1448. [CrossRef]

57. Núñez, L.; D’Aquino, M. Microbicidal activity of clove essential oil (Eugenia Caryophyllata) in human dermal fibroblasts. *Pharm. Biol. 2017*, 55, 1619–1622. [CrossRef] [PubMed]

58. Philip, R.; Dinsuhaimi, S.; Rosdan, S.; Samsudin, A.R.; Shamsuria, O.; Jamalulail, S.M.S. In vitro evaluation of the anti-inflammatory effects of Eugenol and dehydroeugenol in a murine model of allergic asthma. In *Proceedings of the American Thoracic Society International Conference Meetings Abstracts, Dallas, TX, USA, 17–22 May 2019*; Dallas, TX, USA, American Thoracic Society; p. A2184. [CrossRef]

59. Han, X.; Parker, T.L. ‘Anti-inflammatory activity of clove (Eugenia Caryophyllata) essential oil in human dermal fibroblasts. *Pharm. Biol. 2012*, 43, 1255–1260. [CrossRef] [PubMed]

60. Medicherla, S.; Wadsworth, S.; Cullen, B.; Silcock, D.; Ma, J.Y.; Mangadu, R.; Kerr, I.; Chakravarty, S.; Luedtke, G.L.; Dugar, S.; et al. p38 MAPK inhibition reduces diabetes-induced impairment of wound healing. *Diabetes Metab. Syndr. Obes. Targets Ther. 2009*, 2, 91–100. [CrossRef]

61. Philip, R.; Dinsuhaimi, S.; Rosdan, S.; Samsudin, A.R.; Shamsuria, O.; Jamalulail, S.M.S. In vitro evaluation of the growth enhancing or cytotoxic effect of Sticophus species (Gamat) on established human fibroblast cell lines and antimicrobial activity. *Med. J. Malays. 2004*, 59 (Suppl. B), 95–96. [CrossRef]

62. Belloeil, P.; Guerra, B.; Stoicescu, A. *Manual for Reporting on Antimicrobial Resistance within the Framework of Directive 2003/99/EC And Decision 2013/652/EU for Information Derived from the Year 2019*; EFSA Supporting Publications; Wiley: Hoboken, NJ, USA, 2020; Volume 17, p. 1794E. [CrossRef]

63. Roncon, F.P.; Silva, R.C.; Ponci, V.; Oliv, C.R.; Arantes-Costa, F.M.; Caperuto, L.C.; Tiberio, I.C.; Lago, J.H.G.; Prado, C.M. ‘The Role of Peroxisome Proliferator-Activated Receptor γ in Skin Homeostasis, Hypertrophy, and Hypertension.’ *Adv. Wound Care. 2013*, 2, 69–73. [CrossRef]

64. Steinstraesser, L. Evaluation of toxic side effects of clinically used skin antiseptics in vitro. *J. Invest. Dermatol. Symp. Proc. 2006*, 11, 30–35. [CrossRef] [PubMed]

65. Hirsch, T.; Koerber, A.; Jacobsen, F.; Dissemond, J.; Steinau, H.U.; Gatermann, S.; Al-Benna, S.; Kesting, M.; Seipp, H.M. ‘Peroxisome Proliferator-Activated Receptor γ (PPARγ) Impairs Cell Migration.’ *J. Surg. Res. 2011*, 164, 344–350. [CrossRef]

66. Philip, R.; Dinsuhaimi, S.; Rosdan, S.; Samsudin, A.R.; Shamsuria, O.; Jamalulail, S.M.S. ‘Anti-inflammatory effects of Eugenol and dehydroeugenol in a murine model of allergic asthma.’ In *Proceedings of the American Thoracic Society International Conference Meetings Abstracts, Dallas, TX, USA, 17–22 May 2019*; Dallas, TX, USA, American Thoracic Society; p. A2184. [CrossRef] [PubMed]

67. Icre, G.; Wahli, W.; Michalik, L. Functions of the peroxisome proliferator-activated receptor (PPAR) α and β in skin homeostasis, epithelial repair, and morphogenesis. *J. Investig. Dermatol. Symp. Proc. 2006*, 11, 30–35. [CrossRef]

68. Philip, R.; Dinsuhaimi, S.; Rosdan, S.; Samsudin, A.R.; Shamsuria, O.; Zaki, S.M.; Jamalulail, S.M.S. In vitro evaluation of the growth enhancing or cytotoxic effect of Sticophus species (Gamat) on established human fibroblast cell lines and antimicrobial activity. *Med. J. Malays. 2004*, 59 (Suppl. B), 95–96. [CrossRef]

69. Beloeil, P.; Guerra, B.; Stoicescu, A. *Manual for Reporting on Antimicrobial Resistance within the Framework of Directive 2003/99/EC And Decision 2013/652/EU for Information Derived from the Year 2019*; EFSA Supporting Publications; Wiley: Hoboken, NJ, USA, 2020; Volume 17, p. 1794E. [CrossRef]

70. Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Fourth Informational Supplement.* *CLSI 2014*, 34, 100–122. [CrossRef]

71. Ligozzi, M.; Bernini, C.; Bonora, M.G.; De Fatima, M.; Zuliani, J.; Fontana, R. Evaluation of the VITEK 2 system for identification and antimicrobial susceptibility testing of medically relevant gram-positive cocci. *Int. J. Clin. Microbiol. 2002*, 40, 1681–1686. [CrossRef]

72. Sambrook, J.; Russel, D. *Molecular Cloning: A Laboratory Manual*, 3rd ed.; Cold Springs Harbour Laboratory Press: Woodbury NY, USA, 2001.
73. El Ghallab, Y.; Al Jahid, A.; Eddine, J.J.; Said, A.A.H.; Zarayby, L.; Derfoufi, S. *Syzygium aromaticum* L.: Phytochemical investigation and comparison of the scavenging activity of essential oil, extracts and eugenol. *Orient. Pharm. Exp. Med.* 2019, 20, 153–158. [CrossRef]

74. Okur, M.E.; Karadağ, A.E.; Özhan, Y.; Sapıhi, H.; Ayla, Ş.; Daylan, B.; Kültür, S.; Demirci, B.; Demirci, F. Anti-inflammatory, analgesic and in vivo-in vitro wound healing potential of the *Phlomis rigida* Labill. extract. *J. Ethnopharmacol.* 2021, 266, 113408. [CrossRef]

75. Zakaria, A.S.; Afifi, S.A.; Elkhodairy, K.A. Newly Developed Topical Cefotaxime Sodium Hydrogels: Antibacterial Activity and in Vivo Evaluation. *BioMed Res. Int.* 2016, 2016, 6525163. [CrossRef]

76. Muthachan, T.; Tewtrakul, S. Anti-inflammatory and wound healing effects of gel containing *Kaempferia marginata* extract. *J. Ethnopharmacol.* 2019, 240, 111964. [CrossRef]

77. Tasić-Kostov, M.; Arsić, I.; Pavlović, D.; Stojanović, S.; Najman, S.; Naumović, S.; Tadić, V. Towards a modern approach to traditional use: In vitro and in vivo evaluation of *Alchemilla vulgaris* L. gel wound healing potential. *J. Ethnopharmacol.* 2019, 238, 111789. [CrossRef] [PubMed]

78. King, A.J.F. The use of animal models in diabetes research. *Br. J. Pharmacol.* 2012, 166, 877–894. [CrossRef]

79. Muhammad, A.A.; Arulselvan, P.; Cheah, P.S.; Abas, F.; Fakurazi, S. Evaluation of wound healing properties of bioactive aqueous fraction from *Moringa oleifera* Lam on experimentally induced diabetic animal model. *Drug Des. Dev. Ther.* 2016, 10, 1715–1730. [CrossRef] [PubMed]

80. Solarek, W.; Koper, M.; Lewicki, S.; Szczyl, C.; Czarnecka, A.M. Insulin and insulin-like growth factors act as renal cell cancer intratumoral regulators. *J. Cell Commun. Signal.* 2019, 13, 381–394. [CrossRef]

81. Zhang, Z.; Jiang, D.; Wang, C.; Garzotto, M.; Kopp, R.; Wilmot, B.; Thuillier, P.; Dang, A.; Palma, A.; Farris, P.E.; et al. Polymorphisms in oxidative stress pathway genes and prostate cancer risk. *Cancer Causes Control* 2019, 30, 1365–1375. [CrossRef] [PubMed]

82. Schmittgen, T.D.; Livak, K.J. Analyzing real-time PCR data by the comparative CT method. *Nat. Protoc.* 2008, 3, 1101–1108. [CrossRef] [PubMed]

83. Xu, L.; McLennan, S.V.; Lo, L.; Natfaji, A.; Bolton, T.; Liu, Y.; Twigg, S.M.; Yue, D.K. Bacterial load predicts healing rate in neuropathic diabetic foot ulcers. *Diabetes Care. Am. Diabetes Assoc.* 2007, 30, 378–380. [CrossRef]

84. Bancroft, J.D.; Layton, C. *Bancroft’s Theory and Practice of Histological Techniques, Chapter: 10 The Hematoxylins and Eosin, Bancroft’s Theory and Practice of Histological Techniques;* Elsevier: Amsterdam, The Netherlands, 2019. [CrossRef]